Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 21,942

Document Document Title
WO/2016/169028A1
The present invention provides three novel conotoxin peptides, namely κ-CPTx-btl06, κ-CPTx-btl07 and κ-CPTx-btl08, amino acid sequences thereof being shown as SEQ ID NO: 1, 2 and 3 respectively. The present invention also relates to p...  
WO/2016/172224A1
An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding ...  
WO/2016/171249A1
Provided is the compound represented by formula (I) (in the formula, Y1 is O or the like; Z1 is, C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently hydrogen atoms or the like; R1 is a s...  
WO/2016/170353A1
(3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro -5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.  
WO/2016/166480A1
The invention relates to a derivative of general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or pre...  
WO/2016/164089A3
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/...  
WO/2016/163912A1
The invention relates to medicine, and more particularly to neurosurgery and trauma surgery, and can be used for stimulating nerve regeneration through the use of a gene therapeutic construct which codes for vascular endothelial growth f...  
WO/2016/164501A1
In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type ...  
WO/2016/164497A1
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4: ActRIIB complexes...  
WO/2016/161343A2
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...  
WO/2016/157130A1
Macroalgae compositions, processes for the preparation thereof, and applications thereof as a sports nutrition supplement are described. More particularly, a macroalgae composition includes a macroalgae extract including medium chain and...  
WO/2016/158810A1
This agent for the prevention and/or treatment of conditions associated with RAGE/ligand interactions, containing as an active ingredient a compound represented by formula (I): (in the formula, each of the symbols is defined as in the de...  
WO/2016/155661A1
Provided is a compound capable of being used to treat diseases caused by cell proliferation and/or angiogenesis or diseases associated with or accompanied by the cell proliferation and/or the angiogenesis.  
WO/2016/155358A1
Disclosed are a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, pharmaceutical compositions and uses thereof in the preparation of a medicine for inhibiting HIF proline h...  
WO/2016/161343A3
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...  
WO/2016/161294A1
Provided herein are methods and kits for increasing cardiac contraction, increasing mitochondrial activity, and/or increasing oxphos activity. Such methods include use of therapeutically effective amounts of one or more agents that incre...  
WO/2016/156470A1
The present invention relates to formulations containing ultra-deformable drug-free particles and their use in treating soft-tissue soreness, such as delayed onset muscle soreness (DOMS) and exercise-induced muscle soreness. The formulat...  
WO/2016/152519A1
Provided is an external medicine for diffuse plexiform neurofibroma. The external medicine for diffuse plexiform neurofibroma according to the present invention comprises as an active ingredient at least one member selected from the grou...  
WO/2016/149092A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  
WO/2016/148213A1
Disclosed are: any one polypeptide selected from (a) a polypeptide which comprises the amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide which comprises an amino acid sequence produced by deleting, substituting, insertin...  
WO/2016/145935A1
Provided is a series of new poly-fluorosubstituted pyrazolopyrimidine compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors. The compounds have better kinase inhibition selectivity and pharmokinetic properties. ...  
WO/2016/145225A3
A neuromuscular aid for alleviation and prevention of conditions including muscle cramps and spasms. The neuromuscular aid may be in the form of a packet including a composition including 1 wt% to 15 wt% food grade acid. Instructions for...  
WO/2016/144936A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2016/140922A1
The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject inventi...  
WO/2016/138387A1
The invention relates to synthetic polynucleotides encoding fukutin related protein (FKRP). The invention further relates to nucleic acid constructs comprising the synthetic polynucleotides and methods of using these synthetic polynucleo...  
WO/2016/135308A1
Specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of the salts thereof are described, as are processes for the preparation thereof. Also described are a compound of the formula (A), a ...  
WO/2016/135262A1
The invention relates to the field of medicine and particularly to the use of amino-C2-C6-alkyl nitrates or amino-C2-C4-alkyl nitrates or the pharmaceutically acceptable salt thereof for the treatment and prophylaxis of a chronic disease...  
WO/2016/137963A1
Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include a...  
WO/2016/136933A1
A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as...  
WO/2016/135644A1
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.  
WO/2016/133838A1
Disclosed are 2,2'-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvat...  
WO/2016/128358A1
Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of...  
WO/2016/128772A1
The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.  
WO/2016/129140A1
An intraoral rapid disintegration tablet that comprises fine grains, said fine grains having, at the center, a drug substance-containing core containing butylscopolamine bromide and water-insoluble particles and being provided with an in...  
WO/2016/124922A1
A composition comprising CRH, CRH binding protein (CRH-BP), alpha-2 macroglobulin (A2M) and alpha-melanocyte stimulating hormone (alpha-MSH) for use in treatment of a medical condition selected from the list consisting of an ulcer or sof...  
WO/2016/127135A1
Disclosed herein are compounds that are effective for treatment of various disease states. Dosing includes both single administration and regimens of cycling dosages.  
WO/2016/125025A1
A composition for improving muscle metabolism in a subject and methods for manufacturing and using same. Embodiments include compositions having an extract of Rhaponticum and an extract of Rhodiola. An extract of Rhaponticum may include ...  
WO/2016/121923A1
The present invention pertains to a muscle synthesis promoter which exhibits a muscle synthesis promotion action, and with which it is possible to efficiently ingest milk protein. More specifically, the present invention pertains to a mu...  
WO/2016/120647A3
PPARγ controls the expression of the TGFβ family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation. Thus, GDF3 as a secreted extrinsic effector protei...  
WO/2016/120647A4
PPARγ controls the expression of the TGFβ family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation. Thus, GDF3 as a secreted extrinsic effector protei...  
WO/2016/120652A1
PPARγ controls the expression of the TGFβ family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation. Thus, GDF3 as a secreted extrinsic effector protei...  
WO/2016/114322A1
The present invention provides an agent for the prevention and/or treatment of amyotrophic lateral sclerosis (ALS), the agent containing: one or more kinase inhibitors selected from the group consisting of epidermal growth factor recepto...  
WO/2016/112497A1
Provided are a human anti-human interferon alpha (IFNα) antibody and coding gene and application thereof. By combining a gene engineering method with a bacteriophage surface display technology, a plurality of subtype anti-human IFNα ge...  
WO/2016/111347A1
Provided is a drug the active ingredient of which is a compound having antagonistic activity against EP4 receptor in the prevention and/or treatment of disease attributed to activation of EP4 receptor. The compound represented by general...  
WO/2016/111357A1
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...  
WO/2016/108288A1
A method for producing skeletal muscle progenitor cells from pluripotent stem cells, said method comprising the following steps (1) and (2A) or (2B):(1) a step for culturing the pluripotent stem cells in a liquid culture medium containin...  
WO/2016/106626A1
A Bruton's Tyrosine Kinase (Btk) inhibitor compounds of Formula (I), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use of Btk inhibito...  
WO/2016/106625A1
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use ...  
WO/2016/098061A1
Described herein are methods of treating and preventing muscle wasting and muscle loss, using adherent stromal cells and conditioned medium produced thereby.  
WO/2016/097299A1
Compound for treatment of myotonic dystrophy type The present invention relates to a compound, or a salt thereof, and a pharmaceutical composition comprising said compound, or a salt thereof, for use in the prevention and/or treatment of...  

Matches 101 - 150 out of 21,942